secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105022
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q2 net loss narrows to $70.4M; initiates Phase 3 ReDiscover-2 trial
--------------------------------------------------------------------------------

- Net loss of $70.4M ($0.41 per share) vs $92.2M ($0.69) in Q2 2024.
- Cash, equivalents and investments $656.8M, expected to fund operations into 2029.
- RLY-2608 + fulvestrant Phase 1b data: 10.3-month median PFS, 39% ORR in PI3Kα-mutated HR+/HER2- mBC.
- Initiated Phase 3 ReDiscover-2 trial for RLY-2608 + fulvestrant vs capivasertib + fulvestrant.
- R&D expenses decreased to $63.9M from $92.0M due to streamlining and license agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017025105022/0000950170-25-105022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017025105022/rlay-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer